MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

Search

Coherus Biosciences Inc

Затворен

СекторЗдравеопазване

0.8 8.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.74

Максимум

0.81

Ключови измерители

By Trading Economics

Приходи

-5.9M

-57M

Продажби

-47M

7.6M

P/E

Средно за сектора

1.696

40.527

Марж на печалбата

-744.427

Служители

221

EBITDA

115K

-44M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+397.53% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-32M

87M

Предишно отваряне

-7.31

Предишно затваряне

0.8

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Coherus Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.07.2025 г., 19:37 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

M3-Brigade Shares Fall on Merger With ReserveOne

8.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

8.07.2025 г., 23:27 ч. UTC

Пазарно говорене

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8.07.2025 г., 23:27 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.07.2025 г., 23:21 ч. UTC

Пазарно говорене

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8.07.2025 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.07.2025 г., 22:29 ч. UTC

Придобивния, сливания и поглъщания

Capricorn to Pay A$1.5 Million in Cash and Shares

8.07.2025 г., 22:28 ч. UTC

Придобивния, сливания и поглъщания

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8.07.2025 г., 21:58 ч. UTC

Пазарно говорене

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.07.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.07.2025 г., 19:53 ч. UTC

Пазарно говорене

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8.07.2025 г., 19:53 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

8.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8.07.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8.07.2025 г., 19:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower -- Market Talk

8.07.2025 г., 19:11 ч. UTC

Пазарно говорене

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8.07.2025 г., 19:01 ч. UTC

Пазарно говорене

Oil Futures Gain With Support From Products -- Market Talk

8.07.2025 г., 18:49 ч. UTC

Печалби

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8.07.2025 г., 18:41 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Mixed in June -- Market Talk

8.07.2025 г., 18:38 ч. UTC

Пазарно говорене

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8.07.2025 г., 18:23 ч. UTC

Пазарно говорене

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8.07.2025 г., 18:10 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

8.07.2025 г., 18:10 ч. UTC

Пазарно говорене

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8.07.2025 г., 17:24 ч. UTC

Пазарно говорене

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8.07.2025 г., 17:06 ч. UTC

Пазарно говорене

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Coherus Biosciences Inc Прогноза

Ценова цел

By TipRanks

397.53% нагоре

12-месечна прогноза

Среден 4.03 USD  397.53%

Висок 7 USD

Нисък 1.05 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Coherus Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

2

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

0.9209 / 1.05Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.